SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-23-051900
Filing Date
2023-04-28
Accepted
2023-04-28 06:08:12
Documents
8
Period of Report
2023-06-08

Document Format Files

Seq Description Document Type Size
1 DEF 14A tm231911-1_def14a.htm DEF 14A 890776
2 GRAPHIC bc_netincome-4c.jpg GRAPHIC 119237
3 GRAPHIC bc_paidtsr-4c.jpg GRAPHIC 114043
4 GRAPHIC lg_ymabsthera-4c.jpg GRAPHIC 87238
5 GRAPHIC px_01page-bw.jpg GRAPHIC 551328
6 GRAPHIC px_02page-bw.jpg GRAPHIC 815016
7 GRAPHIC px_03page-bw.jpg GRAPHIC 1056682
8 GRAPHIC sg_thomasgad-bw.jpg GRAPHIC 9693
  Complete submission text file 0001104659-23-051900.txt   4268902
Mailing Address 230 PARK AVENUE SUITE 3350 NEW YORK NY 10169
Business Address 230 PARK AVENUE SUITE 3350 NEW YORK NY 10169 212-847-9841
Y-mAbs Therapeutics, Inc. (Filer) CIK: 0001722964 (see all company filings)

IRS No.: 474619612 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-38650 | Film No.: 23859880
SIC: 2834 Pharmaceutical Preparations